

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10521814	
	Filing Date		2006-08-11	
	First Named Inventor	Bipin C.M. Patel		
	Art Unit	1614		
	Examiner Name			
Attorney Docket Number		1768-134		

U.S.PATENTS						<input type="button" value="Remove"/>
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	6017902		2000-01-25	Glass et al.	
	2	6180766	B1	2001-01-30	Schinazi et al.	
	3	6248916	B1	2001-06-19	Kane et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						<input type="button" value="Remove"/>
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS							<div>Remove</div>	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<div><input type="checkbox"/></div>

/D. Jones/ 12/15/08

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DJ/

Application Number	10521814	10521814 - GAU: 1618
Filing Date	2006-08-11	
First Named Inventor	Bipin C.M. Patel	
Art Unit	1614	
Examiner Name		
Attorney Docket Number	1768-134	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	KASUYA, et al., "Synthesis and characterization of HPMA copolymer-aminopropylgeldanamycin conjugates," Journal of Controlled Release, 2001, pp. 203-211, vol. 74. Elsevier Science Publishers B.V., Amsterdam, NL.	<input type="checkbox"/>
	2	KOPEČEK, "Targetable Polymeric Anticancer Drugs," Annals New York Academy of Sciences, 1991, pp. 335-344.	<input type="checkbox"/>
	3	KOPEČEK, "Water soluble polymers in tumor targeted delivery," Journal of Controlled Release, 2001, pp. 147-158, vol. 74. Elsevier Science Publishers B.V., Amsterdam, NL.	<input type="checkbox"/>
	4	MINKO, et al., "Efficacy of the Chemotherapeutic Action of HPMA Copolymer-Bound Doxorubicin in a Solid Tumor Model of Ovarian Carcinoma," Int. J. Cancer, 2000, pp. 108-117, vol. 86. Wiley-Liss, Inc.	<input type="checkbox"/>
	5	MINKO, et al., "HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line," Journal of Controlled Release, 1998, pp. 223-233, vol. 54. Elsevier Science Publishers B.V., Amsterdam, NL.	<input type="checkbox"/>
	6	NOVICK et al., "Linkage of bomated polylysine to glycoside moieties of polyclonal antibody; boronated antibodies as potential delivery agents for neutron capture therapy," Nuclear Medicine and Biology, 2002, pp. 159-167, vol. 29. Elsevier Science Publishers B.V., Amsterdam, NL.	<input type="checkbox"/>
	7	OLSSON et al., "Uptake of a boronated epidermal growth factor-dextran conjugate in CHO xenografts with and without human EGF-receptor expression," Anti-Cancer Drug Design, 1998, pp. 279-289, vol. 13. Oxford University Press	<input type="checkbox"/>
	8	SAKUMA, et al., "Biorecognizable HPMA copolymer-drug conjugates for colon-specific delivery of 9-aminocamptothecin," Journal of Controlled Release, 2001, pp. 365-379, vol. 75. Elsevier Science Publishers B.V., Amsterdam, NL.	<input type="checkbox"/>
	9	SHIAH, et al., "Biodistribution of free and N-(2-hydroxypropyl)methacrylamide copolymer-bound mesochlorin e6 and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts," Journal of Controlled Release, 1999, pp. 145-157, vol. 61. Elsevier Science Publishers B.V., Amsterdam, NL.	<input type="checkbox"/>

/D. Jones/ 12/15/08

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DJ/

Receipt date: 08/30/2007

Application Number	10521814	10521814 - GAU: 1618
Filing Date	2006-08-11	
First Named Inventor	Bipin C.M. Patel	
Art Unit	1614	
Examiner Name		
Attorney Docket Number	1768-134	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

10	SHIAH, et al., "Combination chemotherapy and photodynamic therapy of targetable N-(2-hydroxypropyl) methacrylamide copolymer-doxorubicin/mesochlorin e6-OV-TL 16 antibody immunoconjugates," Journal of Controlled Release, 2001, pp. 249-253, vol. 74. Elsevier Science Publishers B.V., Amsterdam, NL.	<input type="checkbox"/>
11	UHRICH, Kathryn, "Hyperbranched Polymers for Drug Delivery," Trends in Polymer Science, December 1, 1997, pp. 388-393, vol. 5, no. 12. Elsevier Science Publishers B.V., Amsterdam, NL.	<input type="checkbox"/>
12	LU et al., "Design of novel bioconjugates for targeted drug delivery," Journal of Controlled Release, 2002, pp. 165-173, vol. 78. Elsevier Science Publishers B.V., Amsterdam, NL.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/D. Jones/	Date Considered	12/15/08
--------------------	------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.